Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pranshu Bansal

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Cancer Medicine|August 13, 2017
INST OX-05-024: first line gemcitabine, oxaliplatin, and erlotinib for primary hepatocellular carcinoma and bile duct cancers: a multicenter Phase II trialYehuda Z Patt, Waheed Murad, Mohammed H Fekrazad, et al.
The Oncologist|November 22, 2017
Phase II Trial Using a Combination of Oxaliplatin, Capecitabine, and Celecoxib with Concurrent Radiation for Newly Diagnosed Resectable Rectal CancerEmilio P Araujo-Mino, Yehuda Z Patt, Cristina Murray-Krezan, et al.
JCO Oncology Practice|May 23, 2023
Health Data Sharing Perspectives of Patients Receiving Care in CancerLinQ-Participating Oncology PracticesReshma Jagsi, Krithika Suresh, Chris D Krenz, et al.
Elife|July 5, 2022
Genomic landscape of lymphatic malformations: a case series and response to the PI3Kα inhibitor alpelisib in an <i>N</i>-of-1 clinical trialMontaser F Shaheen, Julie Y Tse, Ethan S Sokol, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Cancer Medicine|August 13, 2017
INST OX-05-024: first line gemcitabine, oxaliplatin, and erlotinib for primary hepatocellular carcinoma and bile duct cancers: a multicenter Phase II trialYehuda Z Patt, Waheed Murad, Mohammed H Fekrazad, et al.
The Oncologist|November 22, 2017
Phase II Trial Using a Combination of Oxaliplatin, Capecitabine, and Celecoxib with Concurrent Radiation for Newly Diagnosed Resectable Rectal CancerEmilio P Araujo-Mino, Yehuda Z Patt, Cristina Murray-Krezan, et al.
JCO Oncology Practice|May 23, 2023
Health Data Sharing Perspectives of Patients Receiving Care in CancerLinQ-Participating Oncology PracticesReshma Jagsi, Krithika Suresh, Chris D Krenz, et al.
Elife|July 5, 2022
Genomic landscape of lymphatic malformations: a case series and response to the PI3Kα inhibitor alpelisib in an <i>N</i>-of-1 clinical trialMontaser F Shaheen, Julie Y Tse, Ethan S Sokol, et al.
Pageof 2